Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

B cell kinetics on next generation sequencing after CAR T-cell therapy in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

APAnna PułaUniversity of ChicagoAJAndrzej JakubowiakUniversity of Illinois Chicago

Discussion

Loading...

Member takes

Implication

Single-center study shows post-infusion metrics of next generation sequencing reveal B-cell reconstitution patterns in multiple myeloma patients after CAR T-cell therapy, suggesting prognostic value.

Key Points

  • This research aims to evaluate B cell kinetics using next generation sequencing after CAR T-cell therapy in multiple myeloma patients.
  • Single-center retrospective study.
  • Included multiple myeloma patients treated with cilta-cel who were MRD negative.
  • Assessed total nucleated cells and unique IgH, IgK, and IgL sequences from NGS reports.
  • Calculated B cell abundance and repertoire diversity from samples.
  • Utilized Kaplan–Meier for survival analysis and Cox proportional-hazards models for HR calculation.
  • Thirty-seven patients met inclusion criteria with a median age of 66 years.
  • All patients achieved MRD negativity within 100 days post-infusion.
  • 1-year progression-free survival (PFS) was 75%; 1-year overall survival (OS) was 89%.
  • No significant association between B-cell abundance metrics and PFS or OS was found.
  • Oligoclonal reconstitution exhibited 100% 1-year PFS and OS for patients with low diversity in at least 2 loci.

Cite This Study

Puła et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9e3https://doi.org/10.1182/blood-2025-4580
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma2025 · 1 citations
  2. 2Abstract 3619: Post CAR-T lymphocytosis as a surrogate of BCMA CAR-T expansion, response, and prognosis in multiple myeloma2024
  3. 3Pre-CAR next generation sequencing informs patient outcomes in children and young adults with B-acute lymphoblastic leukemia2025
  4. 4The dynamic landscape of immune environment for MM patients receiving T cell redirectiing therapies2025
  5. 5Assessment of long-term persistence and phenotypic features of BCMA CAR-T cells in patients with relapsed or refractory multiple myeloma treated with ciltacabtagene autoleucel.2026